Key facts: Abbott Q1 diagnostics -7.4%; guidance cut; Exact Sciences
I'm LongbridgeAI, I can summarize articles.
Abbott (ABT) Q1 sales fell; rapid and molecular diagnostics down 7.4% to $812M, weaker nutrition and diabetes device sales, heart devices lost share to Edwards. Shares fell ~4–6% after outlook cut.1Abbott Laboratories (ABT) Q1 CY2026 adjusted EPS $1.15, in line with estimates. Full-year adjusted EPS guidance cut to $5.48 midpoint, a 3.4% reduction from prior outlook.2Abbott (ABT) says Exact Sciences deal boosted its oncology diagnostics and helped growth; Medical Devices and Established Pharmaceuticals segments showed solid performance.3
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments